Definium Therapeutics (DFTX) EBITDA (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of EBITDA data on file, last reported at -$59.2 million in Q1 2026.

• On a quarterly basis, EBITDA fell 84.15% year-over-year to -$59.2 million in Q1 2026; TTM through Mar 2026 was -$193.4 million, a 69.81% decrease from a year earlier, with the FY2025 full-year figure at -$166.3 million, down 60.04% from the prior year.
• EBITDA for Q1 2026 stood at -$59.2 million, down from -$47.6 million in the prior quarter.
• Over the last five years, EBITDA for DFTX reached as high as -$13.9 million in Q4 2022 and fell as low as -$59.2 million in Q1 2026.
• Historically, EBITDA has averaged -$28.8 million across 5 years, with a median of -$24.5 million in 2024.
• Across the five-year window, EBITDA soared 62.53% in 2022 and slumped 84.21% in 2025, its largest moves.
• Year by year, EBITDA stood at -$13.9 million in 2022, then plunged by 59.75% to -$22.2 million in 2023, then sank by 46.19% to -$32.5 million in 2024, then plunged by 46.57% to -$47.6 million in 2025, then slipped by 24.47% to -$59.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$59.2 million in Q1 2026, -$47.6 million in Q4 2025, and -$45.7 million in Q3 2025.